Cosibelimab is a high-affinity, fully human PD-L1-blocking monoclonal antibody that binds to PD-L1 and inhibits its interaction with PD-1; it possesses a functional Fc domain capable of inducing antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC)-mediated killing of PD-L1-positive cell lines, including lymphoma cells.